Stockreport

RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa

REGENERX BIOPHARMS INC  (RGRX) 
NASDAQ:AMEX Investor Relations: regenerx.com/investors
PDF ROCKVILLE, Md., Aug. 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company foc [Read more]